Member Info for Hulver

So yesterday's tweets: could relate to CBR for HIV and testing progress, perhaps?
We know they have been working on that with some success from earlier information Hemo provided.

CBR testing going well perhaps - Another one (virus) bites the dust.

.....and for those that remember the Gagarin quote, coincidence or not (?), this song starts with "poyekhali".

Based on the volume of alcohol Tillywhiz is administering regularly to us all at the moment - I reckon Diageo must be a fair bet to smash expectations with its next market update.

....and as someone with investment experience said to me when I mentioned that I was starting to invest in biotech stocks

".....if you can find one that becomes the subject of a bidding war...."

well I have always thought that could be the case here, if at any point that is to happen.

LTH, irrespective of the share price shouldn't we just be attending the 2023 AGM (and annually thereafter), with the shareholders AGM meal to follow, after all it's the success of the science, the enjoyment of this investment story and our connection through it that counts. If we all attended in person .. now that would be good.

D-G,

Indeed a new word is needed - its Micronormous(e) !

So here we are in the liminal space between no longer ....... and ....... not yet.

It seems we are onto the next chapter in this epic, now the fountain (of cures) springs.

Well done to the well-researched and resilient that held throughout the last chapter (lengthy as it was) and hopefully added on the way down or at the bottom.

Beware the new 'de-risking' risk in the next chapter as "The HEMO Story" unfolds.

GLA

In December he tweeted this in reply to the open question who was going to be in San Francisco for JPM2023

Vladislav Sandler
@vmsandler

?Replying to ?
?@chrissyfarr
?I am?
?1:11 am · 14 Dec 2022

now consider that in the context of the 'my favourite ticker' tweet........ is that a pure coincidence or .......?

So before xmas Vlad tweeted that he would be in San Francisco attending the JPM Healthcare Conference which starts tomorrow and incorporates the Wuxi AppTec Global Forum on Tuesday.

https://www.jpmorgan.com/solutions/cib/insights/health-care-conference

https://wxpress.wuxiapptec.com/events/wuxi-global-forum-2023/

Other Hemo news: Michael Haugbro's continued rapid promotion in November to Senior Scientist (remember, his chemical bait and trap research work and recruitment less than two years ago seemed a natural fit with project CBR). Vlad, building and retaining a very talented team - from a (hoping to be very) long term shareholder this is good to see.

https://www.linkedin.com/in/michael-haugbro-0a6a0395?original_referer=https%3A%2F%2Fwww.google.com

Be Careful: "De-risking" - this could be an emerging risk; a while ago I thought that might happen.

Status: Shares not for sale.
GLA

So you'd need a ticker for ?

- a spin-off ?? (this may not be outwith the bounds of possibility, I guess)
- a new business IPO, perhaps unrelated to HEMO ??

There was also a tweet referencing Euronext in October and suggestions of European trips.

hmmm....

Didn't Vlad mention that he was going to be at another conference this coming week?

Exodus 3 again perhaps? - he has given a nod to that passage before (it was perhaps 12 - 24 months ago; after all we have been a long time in this wilderness) - maybe 'due time' is near.

JHFH, I don't think any of us LTH invested in Hemo because we believed Hemo's biotech was 'average', so is it not an injustice to be evaluate Hemo against an average valuation? - Vlad is smarter than the average bear (well mostly, perhaps!).

https://www.youtube.com/watch?v=c5zKpr5gmgk

.........and whilst none of us are sure what's going on, in my opinion Hemo is only just getting started too, potentially they have a fountain!

We've yet to understand what the below appointment achieved, if anything; but at the time it suggested potential for introducing new investors. However given Vlad, in the 2022 summer webinar (a year later), seemed very dismissive of Walt's involvement is he even still involved, and was Walts perhaps only there to pacify a large investor that has now left the ship. Can anyone confirm his continued involvement or otherwise?

"26 July 2021
Appointment of Business Advisor & Board Observer

Dr Alan E. Walts joins Hemogenyx Pharmaceuticals team; renowned business leader brings industry experience in corporate and private venture capital, business development, R&D and general management.

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces the appointment of Dr Alan E. Walts as a Board observer and business advisor.

Dr Walts is a US-based Venture Partner with Advent Life Sciences, a position he has held since January 2014. Dr Walts currently serves as a Director and audit committee member at Eloxx Pharmaceuticals (NASDAQ: ELOX), and as Executive Chairman of Artax Biopharma and PIC Therapeutics. He is also a founder, Director and Treasurer of The Termeer Foundation, a public 501(c)(3) organization founded in 2019. Dr Walts is currently an independent Director of Neuroelectrics Corp, and a business advisor and board observer of several private companies including Amylyx Pharmaceuticals, Arrakis Therapeutics, and Alpha Anomeric. Dr Walts' previous board and business advisory experience includes X4 Pharmaceuticals, Aura Biosciences, and Arrakis Therapeutics. Dr Walts has over 25 years of industry experience at Genzyme in business development, business strategy, research and development, general management, and venture capital. Prior to leaving Genzyme in 2013, Dr. Walts most recently managed Genzyme's corporate venture fund, Genzyme Ventures (now Sanofi Ventures). Following Genzyme's landmark sale to Sanofi, he served as a business advisor to founding Chairman and CEO of Genzyme Henri Termeer from 2013-2017, and worked closely with Henri on founding and investing in early-stage companies.

Dr Walts received a Ph.D. in chemistry from MIT in 1985, carried out post-doctoral research in biochemistry at MIT with Professor Christopher Walsh, and completed the executive Program for Management Development at Harvard Business School.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
"We are excited to welcome Dr Alan Walts as business advisor and Board observer. Alan's rich experience and deep insight into the biopharmaceutical industry will undoubtedly help to accelerate Hemogenyx Pharmaceuticals' significant development pipeline."

Dr Alan Walts commented:
"I am excited about the potential of Hemogenyx Pharmaceuticals' technology and I look forward to working with Dr Sandler and the board of Hemogenyx Pharmaceutical"."

Suffering a small charge of less than 15% to receive clean money - there's another possible reason for you to mull over.

There are no doubt many other reasons you could consider/suggest too, if you wanted to; but what other shareholders are doing should really be of little concern. Such things affect the share price only.

Be happy that MH, ES and ST all actively engaged in the growing business - are there because of Hemo's biotech fountain and what it has the potential to achieve.

For the many (I hope) that are also interested in the progress of the science, below is a link to a very recent and insightful webinar given by Dr Koen van Besien

https://www.youtube.com/watch?v=ZxYHwHEK1r8

This is subject is his mastery and his signing up to Hemo perhaps gives an indication of the prospects of Hemo's work in resolving some of the issues that he discusses here.

For the few that are just interested in the share price (to save you having to watch it through) one of the early slides discloses that he has an equity interest in Hemo. It did not disclose any other equity interests!

Proverbs: 2 v 6

https://biblia.com/bible/esv/proverbs/2/6

I think we've been short-changed on this board.

the later photo is Tavistock Square home of the BMA

or maybe

https://bmjresearchforum.bmj.com/about-bmjresearchforum/

So when the facilities are fully approved to undertake the work they are designed for (which seems to be the detailed process we are going through now), do people consider that Hemo will, when not requiring them for its own testing purposes, offer to insource manufacturing and testing work for other institutions and thereby maximise the facilities' potential; at the same time generating an alternative income stream to help with covering operating/staff costs. The shortage of facilities for manufacturing and testing and delays experienced because of it have been widely reported.

Initially I thought that this statement may have just been put out to placate shareholders with regard to funding requirements (as I thought it may only get in the way and increase risk to Hemo's own requirements for them) but now I am considering that this does seem to be a viable proposition and would provide an additional longer term business offering from Hemo.

Intriguing - is the word I would use to describe this investment.

It's around this time of year that new words are put forward for entry in the English dictionary so how about a bit of distraction from the share price by compiling some words that have proven to no longer have the meaning that they used to (or we thought they still had) for entry in a new dictionary - 'Vlad's Alternative Dictionary'.

I shall put forward firstly:

'blip' - an unexpected and exceedingly long term downturn (especially one which is hopefully not permanent)